NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis $1.95 -0.01 (-0.51%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Sangamo Therapeutics Stock (NASDAQ:SGMO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sangamo Therapeutics alerts:Sign Up Key Stats Today's Range$1.89▼$2.1150-Day Range$0.78▼$2.8752-Week Range$0.30▼$3.18Volume6.70 million shsAverage Volume12.91 million shsMarket Capitalization$406.87 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company OverviewSangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.Read More… Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Sangamo Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks44th Percentile Overall ScoreSGMO MarketRank™: Sangamo Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 672nd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingSangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Sangamo Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.50) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sangamo Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.10% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sangamo Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.10% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sangamo Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.44 News SentimentSangamo Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Sangamo Therapeutics this week, compared to 2 articles on an average week.Search Interest28 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows20 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sangamo Therapeutics' insider trading history. Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Stock News HeadlinesWhat is HC Wainwright's Estimate for SGMO FY2028 Earnings?November 17, 2024 | americanbankingnews.comWells Fargo Gives a Hold Rating to Sangamo Biosciences (SGMO)November 15, 2024 | markets.businessinsider.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…November 21, 2024 | Porter & Company (Ad)Sangamo Biosciences: Promising Financial Position and Strategic FDA Alignment Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comQ3 2024 Sangamo Therapeutics Inc Earnings CallNovember 13, 2024 | uk.finance.yahoo.comRBC Capital Remains a Hold on Sangamo Biosciences (SGMO)November 13, 2024 | markets.businessinsider.comSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSangamo options imply 21.0% move in share price post-earningsNovember 13, 2024 | markets.businessinsider.comSee More Headlines SGMO Stock Analysis - Frequently Asked Questions How have SGMO shares performed this year? Sangamo Therapeutics' stock was trading at $0.5433 at the start of the year. Since then, SGMO stock has increased by 258.9% and is now trading at $1.95. View the best growth stocks for 2024 here. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The biopharmaceutical company had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative trailing twelve-month return on equity of 264.16%. Who are Sangamo Therapeutics' major shareholders? Sangamo Therapeutics' top institutional shareholders include Wasatch Advisors LP (9.34%), Geode Capital Management LLC (1.02%), Jacobs Levy Equity Management Inc. (0.71%) and Charles Schwab Investment Management Inc. (0.53%). Insiders that own company stock include Biogen Inc and John Markels. View institutional ownership trends. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Intel (INTC), MSP Recovery (LIFW), MSP Recovery (LIFW) and Abrdn Asia-Pacific Income Fund (FAX). Company Calendar Last Earnings11/12/2024Today11/20/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees480Year Founded1995Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+259.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-257,830,000.00 Net Margins-257.87% Pretax Margin-257.89% Return on Equity-264.16% Return on Assets-107.24% Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$176.23 million Price / Sales2.31 Cash Flow$0.04 per share Price / Cash Flow55.68 Book Value$0.47 per share Price / Book4.15Miscellaneous Outstanding Shares208,650,000Free Float202,805,000Market Cap$406.87 million OptionableOptionable Beta1.10 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:SGMO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.